are they stopping compounded semaglutide compounding GLP-1s comes to an end - Compounded semaglutidereviews no longer allowed to make cheaper versions of semaglutide Are They Stopping Compounded Semaglutide? Navigating the Shifting Landscape of GLP-1 Medications

Compoundedtirzepatide banned The question of whether compounded semaglutide is being stopped is a pressing one for many individuals seeking weight management and diabetes control. Recent regulatory actions by the U.S. Food and Drug Administration (FDA) have indeed led to significant changes in the availability of these customized medications. While the era of widespread, unrestricted compounding of semaglutide and tirzepatide is ending, the situation is nuanced and involves specific deadlines and directives.

The primary driver behind these changes is the resolution of the national semaglutide shortage.Sprout Health GLP-1 Weight Loss in 2026 On February 21, 2025, the FDA officially removed semaglutide injection products from its drug shortage list.2025年4月25日—With Pittman's verdict,large compounders will still have only until May 22to comply and stop producing their versions of semaglutide. Smaller, ... This marks a pivotal moment, as the FDA's stance on compounded versions of drugs experiencing shortages has always been to allow compounding as a temporary measure.FDA clarifies policies for compounders as national GLP-1 ... Once the shortage is resolved, the focus shifts to ensuring the availability and safety of FDA-approved medications like Ozempic and Wegovy (which contain semaglutide) and Zepbound (which contains tirzepatide).

Consequently, outsourcing facilities and state-licensed pharmacies that previously produced compounded semaglutide have been given specific deadlines to stop compounding tirzepatide and semaglutide. For large compounders, the deadline to comply and stop producing their versions of semaglutide was May 22, 2025. For 503a pharmacies, the directive is to stop compounding, distributing, or dispensing semaglutide products that are not FDA-approved.State-licensed pharmacies must stop making most compounded semaglutide(copies of Novo Nordisk's Wegovy and Ozempic) by April 22, and larger outsourcing ... Essentially, this means that compounded semaglutide and similar GLP-1 medications are no longer allowed to make cheaper versions of semaglutide if FDA-approved alternatives are availableCompound versions of GLP-1 drugs for weight loss halted ....

This shift signifies the end of the widespread availability of compounded GLP-1s. Previously, many telehealth platforms, such as Hims & Hers, offered compounded semaglutide, often with added B12. However, due to FDA warnings and enforcement actions, some of these platforms are re-evaluating their services. While some initially indicated a desire to continue offering compounded semaglutide, the regulatory pressure appears to be leading to a cessation of these practices. Hims & Hers, for instance, has stated they will stop offering access to certain treatments following FDA warnings, although they may be exploring alternative weight loss options.

It's crucial to understand that this does not mean compounded medications are entirely banned. The FDA's guidance specifically addresses situations where FDA-approved drugs are available and not in shortage.Semaglutide officially declared no longer on shortage For entities operating as outsourcing facilities under Section 503B of the FD&C Act, strict adherence to these regulations is expected.If you read the FDA's announcement, it says 503a pharmaciesmust stopcompounding, distributing, or dispensing semaglutide products that are ... The FDA has received adverse event reports associated with compounded semaglutide, underscoring their concern about the safety and efficacy of these non-FDA-approved versions.Patients struggle as compounded GLP-1 access rapidly shrinks As of July 31, 2025, the FDA had received 605 reports of adverse events linked to compounded semaglutideThe FDA has instructedcompoundingpharmacies tostopmaking manycompoundedGLP-1 drugs when FDA- approved versions are again available. Why ....

For patients who have been relying on compounded semaglutide, this transition can be challenging. The semaglutide and tirzepatide shortages are officially over, but the availability of compounded versions is rapidly shrinking.Hims & Hers plays down GLP-1 risk in Q4 earnings This has led some physicians to explore older, more established medications as alternatives. The original intent of compounding was to fill gaps during shortages, and with the shortage resolved, the landscape is returning to FDA-approved pathways.

When considering compounded semaglutide, it's important to differentiate between legitimate uses and the current regulatory environment. While the FDA has removed semaglutide from the shortage list and is prohibiting compounded versions of GLP-1s, the discussion around compounded semaglutide reviews and the effectiveness of these formulations continues. However, for many, the ability to access these customized treatments is indeed coming to an end.

In summary, the answer to "are they stopping compounded semaglutide" is largely yes, in the context of the FDA's directives following the resolution of the semaglutide shortage on Feb 21, 2025. While the semaglutide drug shortage is officially over, the transition period for compounding pharmacies has come with strict deadlines3天前—He also stated that Hims' weight loss business is durable even in the “draconian scenario” in whichtheyhad tostopofferingcompoundingGLP-1s .... The focus is now on FDA-approved semaglutide products and ensuring patient safety in the evolving world of GLP-1 medications2026年2月4日—As of July 31, 2025, the FDA has received: 605 reports of adverse events associated with compounded semaglutide.. While it may feel like compounding GLP-1s comes to an end for many, understanding the specific FDA guidelines and individual patient needs remains paramount.